CACrown ArchivesThe cinema collection
EN/FR
Search
Menu
Research dossier · General Reference

NH130

pharmaceutical compound

Cross-disciplinary reference desk with index cards, atlas, dictionary and catalogue
General referenceInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionAug 29, 2026
Entity authorityQ138019796 ↗
Source-derived summary

NH130 is a highly selective serotonin 5-HT2A receptor inverse agonist which is under development for the treatment of Parkinson's disease psychosis. It is taken orally. The drug's time to peak levels is 3.0 to 4.5 hours and its elimination half-life is 13.7 to 18.2 hours. NH130 is under development by Jiangsu Nhwa Pharmaceutical in China. As of November 2025, it is in phase 2 clinical trials.

Editorial summary

“NH130” enters the record as pharmaceutical compound. Crown Archives preserves that source wording while asking what NH130, pharmaceutical and compound can confirm, complicate or overturn.

Editorial reviewA concise reference frame for defining the subject, testing terminology and identifying the institution closest to the evidence. The current lead gives the account dated anchors—2025—that can be checked directly. The selected authority fields contribute no independent date. Its strongest next move is a source search built around NH130, pharmaceutical and compound.
Editorial analysis

Why this record matters

“NH130” is worth following because a concise public description often conceals a longer documentary argument. Here, NH130, pharmaceutical and compound provides the most credible route into that argument.

Evidence profile

Named sources, stable identifiers and responsible institutions provide the strongest route from overview to verifiable evidence. The source revision retrieved here is dated Aug 29, 2026. The linked authority identifier is Q138019796. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2025.

Critical limits

The absence of detail may reflect summary conventions rather than a lack of surviving documentation. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Use the entry as an orientation point, then follow its citations and revision history. Names, dates and institutional relationships should be checked against the original record.

Best used for
  • Subject orientation
  • Search vocabulary
  • Locating named sources
Verify next

The closest primary source, responsible institution and strongest cited specialist reference.

Three-step research path

  1. Establish the record: confirm the title “NH130”, its source revision and the description used here.
  2. Expand the search: follow NH130 primary sources, NH130 archive and NH130 research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “NH130”?
  2. Which cited source is closest to the event, object or claim?
  3. Which institution is responsible for the underlying evidence?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from “NH130” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.